Fiscal Year:
2001
Title:
Novel Cannabinoid Receptor Agonists as Analgesics
Agency:
HHS
Contract:
N/A
Award Amount:
$157,110.00
Abstract:
DESCRIPTION (provided by applicant): Pain is a serious, debilitating condition
that is undertreated because because of the dose-limiting side effects of
currently used therapeutics. Agonists at the cannabinoid (CB) receptors,
including delta-9-tetrahydrocannabinol, have been shown to relieve pain in
humans, but their use has been limited due to their psychotropic effects and
their possible abuse potential. Most studies on the role of CB receptors in
analgesia have focused on GB2 receptors in the central nervous system. Recent
data have indicated a role for CB2 receptors in the peripheral nervous system
in ameliorating both inflammation and the accompanying pain. We propose to
develop a new class of analgesics that are CB2 receptor-selective agonists that
may exhibit a dual mechanism of action to provide a one/two punch in
alleviating inflammatory pain by acting on peripheral neurons to inhibit pain
transmission and by reducing inflammation. Adolor Corporation is a
biopharmaceutical company with a proven ability to discover and develop
non-narcotic analgesic that lack central nervous system liabilities. We will
use our expertise to discover and develop CB2 receptor-selective agonists that
are effective analgesics in inflammatory pain.
PROPOSED COMMERCIAL APPLICATION:
Not Available
Principal Investigator:
Robert N. Dehaven
Small Business Information at Submission:
ADOLOR CORPORATION
371 PHOENIXVILLE PIKE MALVERN, PA 19355
EIN/Tax ID:
311429198
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned:
No
Minority-Owned:
No
HUBZone-Owned:
No